Offerings

What's Going On With Nyxoah Stock Tuesday?

Vandana Singh — Tue, 09 Jun 2026 13:04:29 +0000

Nyxoah SA (NASDAQ:NYXH) stock is up during Tuesday’s premarket session. Year to date, the stock has plunged almost 70%.

On Friday, the company priced its $95 million underwritten public offering. The offering aims to fund various initiatives, including commercialization efforts and research and development for its Genio system, a treatment for Obstructive Sleep Apnea.

The offering is significant as it reflects Nyxoah’s commitment to expanding its market presence and enhancing its product offerings.

Nyxoah Raises $95 Million Via Equity

The public offering consists of approximately 55.2 million ordinary shares priced at $1.72 each, with a 30-day option for underwriters to purchase additional shares.

The proceeds are intended for expanding commercialization activities in the U.S. and advancing R&D for product enhancements and new technologies.

data-variant="card"
data-news-mode="manual"

Get Summer-Ready at Prima Medicine's "Summer Shape & Glow Event" -- A Fun, Feel-Good Wellness Experience You Won't Want to Miss

PRNewswire — Tue, 09 Jun 2026 12:56:00 +0000

FAIRFAX, Va., June 9, 2026 /PRNewswire/ -- Summer is calling — and there's no better time to feel confident, energized, and glowing from the inside out. Prima Medicine is excited to invite the community to the "Summer Shape & Glow Event," an exciting, one-of-a-kind wellness experience designed to help you refresh, recharge, and feel your absolute best this season — with FREE event tickets and complimentary wellness sessions available through registration.

Join us on Thursday, June 18, 2026, from 4:00 PM to 6:00 PM at 3903 Fair Ridge Drive Parking Lot, Fairfax, VA 22033, where an interactive wellness bus experience brings innovative, non-invasive wellness treatments straight to you in a fun, welcoming atmosphere.

Whether you're looking to tone up for summer, strengthen your core and pelvic wellness, boost confidence, or ...

Full story available on Benzinga.com

Rocket Companies Announces Offering of Senior Notes due 2031 and Senior Notes due 2034

PRNewswire — Tue, 09 Jun 2026 12:29:00 +0000

DETROIT, June 9, 2026 /PRNewswire/ -- Rocket Companies, Inc. (NYSE:RKT) (the "Company"), the Detroit-based fintech platform including mortgage, real estate, title and personal finance businesses, is proposing to issue and sell $600,000,000 aggregate principal amount of senior notes due 2031 and $600,000,000 aggregate principal amount of senior notes due 2034 (collectively, the "Notes") in an offering that will be exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act") (the "Offering").

The Notes will initially be fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by each of the Company's direct and indirect domestic subsidiaries that are guarantors under the Company's existing senior notes.

The Company intends to use the proceeds from the Offering to repay Rocket Mortgage, LLC's 2.875% Senior Notes due 2026 and certain other indebtedness of the Company and its subsidiaries.

The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act, and outside the United States, to non-U.S. investors pursuant to Regulation S. The Notes and related guarantees will not ...

Full story available on Benzinga.com

ALLEGIANT TRAVEL COMPANY ANNOUNCES LAUNCH OF TENDER OFFER AND CONSENT SOLICITATION FOR ITS 7.250% SENIOR SECURED NOTES DUE 2027

PRNewswire — Tue, 09 Jun 2026 12:10:00 +0000

LAS VEGAS, June 9, 2026 /PRNewswire/ -- Allegiant Travel Company (NASDAQ:ALGT) (the "Company," "we," "us," or "our") announced today that it is commencing a tender offer (the "Tender Offer") to purchase for cash any and all of its outstanding $403,009,000 remaining aggregate principal amount of 7.250% Senior Secured Notes Due 2027 (the "Notes"). In connection with the Tender Offer, the Company is also seeking consents (the "Consent Solicitation") to proposed amendments (the "Proposed Amendments") to the Indenture, dated as of August 17, 2022 (the "Indenture"), which governs the Notes, that would eliminate most of the restrictive covenants and certain events of default applicable to the Notes, and amend certain other provisions applicable to the Notes.

Information related to the Notes and other information relating to the Tender Offer and Consent Solicitation are listed in the table below. The terms and conditions of the Tender Offer and Consent Solicitation are described in greater detail in the Offer to Purchase and Consent Solicitation Statement, dated June 9, 2026 (the "Statement"), which holders of the Notes (each a "Holder" and collectively the "Holders") should carefully read before making any decision with respect to the Tender Offer and Consent Solicitation.

CUSIP No		Title of Security		Outstanding Principal Amount		Tender Offer Consideration ⁽¹⁾		Early Tender Premium ⁽²⁾		Total Consideration⁽³⁾
144A: 01748X AD4 Reg S: U0177P AC2		7.250% Senior Secured Notes due 2027		$403,009,000		$955.00		$50.00		1,005.00


(1)	Per $1,000 principal amount of Notes validly tendered and not withdrawn at or prior to the Expiration Time (as defined below) and excludes accrued and unpaid interest.
(2)	Per $1,000 principal amount of Notes validly tendered and not withdrawn at or prior to the Early Tender Deadline (as defined below).
(3)	Includes the Tender Offer Consideration plus the Early Tender Premium (as defined below) and excludes accrued and unpaid interest.

Holders who validly tender their Notes and thereby deliver their consents at or prior to 5:00 p.m., New York City time, on June 23, 2026, unless extended or earlier terminated by the Company (the "Early Tender Deadline") will be eligible to receive total consideration (the "Total Consideration") of $1,005.00 per $1,000 principal amount of Notes, which includes the consideration for the Notes validly tendered (and not validly withdrawn), pursuant to the Statement, of $955.00 per $1,000 principal amount of such Notes (the "Tender Offer Consideration") and the early tender ...

Full story available on Benzinga.com

ALLEGIANT TRAVEL COMPANY ANNOUNCES OFFERING OF SENIOR SECURED NOTES

PRNewswire — Tue, 09 Jun 2026 12:01:00 +0000

LAS VEGAS, June 9, 2026 /PRNewswire/ -- Allegiant Travel Company (NASDAQ:ALGT) (the "Company," "we," "us," or "our") has commenced an offering of $500.0 million in aggregate principal amount of Senior Secured Notes due 2031 (the "Notes") to investors in a private offering.

Each of the Company's subsidiaries, other than Dustland, LLC and certain other insignificant subsidiaries (the "Guarantors"), will guarantee the Notes. The Notes and the related guarantees will be secured by security interests in substantially all of the property and assets of the Company and the Guarantors, excluding aircraft, aircraft engines, real property and certain other assets (the "Collateral"). Some of the Collateral, other than the property and assets ...

Full story available on Benzinga.com

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

PRNewswire — Tue, 09 Jun 2026 02:22:00 +0000

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $27.00 per share, before underwriting discounts and commissions, and the pre-funded warrants are being sold at a public offering price of $26.9999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.0001 per share. In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1,666,669 shares of its common stock at the public offering price per share, before underwriting discounts and commissions. The aggregate gross proceeds to IDEAYA from this offering are expected to be approximately $300.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. The offering is expected to close on or about June 10, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for this offering.

Full story available on Benzinga.com

APOTEX HEALTH CORP. UPSIZES ITS INITIAL PUBLIC OFFERING

PRNewswire — Tue, 09 Jun 2026 01:30:00 +0000

/Not for distribution to U.S. news wire services or dissemination in the United States./

TORONTO, June 8, 2026 /CNW/ - Apotex Health Corp. ("Apotex" or the "Company") today announced the upsize of its previously announced initial public offering (the "Offering") of common shares of the Company (the "Common Shares"). The Company now expects the Offering to consist of between 54,166,670 and 65,000,005 Common Shares at a price per Common Share between $20.00 and $24.00 (the "Offering Price"), for gross proceeds of approximately $1.3 billion.

The Offering consists of a treasury offering by Apotex of between 35,416,666 and 42,500,000 Common Shares at the Offering Price, for gross proceeds of approximately $850 million to Apotex, and a secondary offering by certain shareholders of the Company (the "Selling Shareholders") of between 18,750,004 and 22,500,005 Common Shares at the Offering Price, for gross proceeds of approximately $450 million to the Selling Shareholders. The Selling Shareholders are expected to grant an over-allotment option to the underwriters to purchase up to an additional 8,125,000 to 9,750,000 Common Shares at the Offering Price, exercisable at any time, in whole or in part, until 30 days after the closing date of the Offering, to cover over-allotments, if any, and for market stabilization purposes.

Assuming an Offering size of approximately $1.3 billion and an Offering Price of $22.00 per Common Share (the midpoint of the Offering Price range), following completion of the Offering, an aggregate of 231,726,671 Common Shares will be issued and outstanding on a non-diluted basis (or 247,662,946 Common Shares on a fully diluted basis) and SK Artemis Holdings, II, LLC and API Investment LP will beneficially hold approximately 54.3% and 14.0% of the Common Shares (on a non-diluted basis), respectively (or 50.6% and 14.0% of the Common Shares (on a non-diluted basis) if the Over-Allotment Option is exercised in full).

The Offering is being made through a syndicate of underwriters led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as co-lead managers, joint global coordinators and joint lead bookrunners, BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, and ...

Full story available on Benzinga.com

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

PRNewswire — Tue, 09 Jun 2026 01:23:00 +0000

ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public offering of 2,975,000 shares of common stock at a public offering price of $11.00 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public offering price of $10.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant. All of the securities to be sold in the offering are being offered by Eloxx. Eloxx expects to receive gross proceeds of $66.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Eloxx. The shares of common stock are expected to begin trading on the Nasdaq Capital Market on June 9, 2026, under the symbol "ELOX". The offering is expected to close on June 10, 2026, subject to the satisfaction of customary closing conditions.

Full story available on Benzinga.com

1911 Gold Announces Overnight Marketed Offering

PRNewswire — Mon, 08 Jun 2026 21:13:00 +0000

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER, BC, June 8, 2026 /CNW/ - 1911 Gold Corporation ("1911 Gold" or the "Company") (TSXV:AUMB) (OTCQX: AUMBF) (FRA: 2KY) is pleased to announce that it has filed a preliminary short form prospectus with the securities commissions in all Provinces of Canada (except Québec), in connection with an overnight marketed public offering (the "Offering") comprised of: (i) common shares ("Common Shares") of the Company (the "Offered Shares"); (ii) Common Shares to be issued as "flow-through shares" within the meaning of the Income Tax Act (Canada) (the "Tax Act"), which will be used to incur "Canadian exploration expenses" within the meaning of the Tax Act from or above the surface of the earth (the "CEE Series 1 Flow-Through Shares"); (iii) Common Shares to be issued as "flow-through shares" within the meaning of the Tax Act, which will be used to incur "Canadian exploration expenses" within the meaning of the Tax Act (the "CEE Series 2 Flow-Through Shares"); and (iv) Common Shares to be issued as "flow-through shares" within the meaning of the Tax Act, which will be used to incur "Canadian development expenses" within the meaning of the Tax Act (the "CDE Flow-Through Shares").

The Offering will be conducted through a syndicate of underwriters led by Roth Canada, Inc. (the "Lead Underwriter"), as lead underwriter, BMO Capital Markets (together with the Lead Underwriter, the "Joint Bookrunners"), as joint bookrunners, and a syndicate of underwriters (together with the Joint Bookrunners, the "Underwriters").

Final pricing, the number of Offered Shares, CEE Series 1 Flow-Through Shares, CEE Series 2 Flow-Through Shares and CDE Flow-Through Shares to be sold, and the gross proceeds of the Offering will be determined in the context of the market at the time of entering into of a definitive underwriting agreement between the Company and the Underwriters.

The Company intends to grant the Underwriters an option, exercisable in whole or in part, at any time and from time to time for a period of 30 days from and including the closing of the Offering, to purchase for resale (or arrange for purchase by substituted purchasers) up to such number of additional Offered Shares on the same terms as the Offered Shares, as is equal, in the aggregate, to 15% of the number of offered securities sold under the Offering, to cover over-allotments, if any, and for market stabilization purposes (the "Over-Allotment Option").

The securities to be issued under the Offering will be offered by way of a final ...

Full story available on Benzinga.com

FSK Completes Public Offering of $900,000,000 7.500% Unsecured Notes Due 2031

PRNewswire — Mon, 08 Jun 2026 20:20:00 +0000

PHILADELPHIA and NEW YORK, June 8, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK) today announced that it has completed its previously announced offering of $900,000,000 in aggregate principal amount of its 7.500% unsecured notes due 2031 (the "Notes"). BofA Securities, Inc., BMO Capital Markets Corp., J.P. Morgan Securities LLC, KKR Capital Markets LLC, RBC Capital Markets, LLC and SMBC Nikko Securities America, Inc. are acting as joint book-running managers for this offering. HSBC Securities (USA) Inc., ING Financial Markets LLC, Mizuho Securities USA LLC, MUFG Securities Americas Inc., TD Securities (USA) LLC, Truist Securities, Inc., Barclays Capital Inc., BNP Paribas Securities Corp., CIBC World Markets Corp., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, SG Americas Securities, LLC, UBS Securities LLC and Standard Chartered Bank are acting as joint lead managers for this offering. ICBC Standard Bank Plc, Keefe, Bruyette & Woods, Inc., Lucid Capital Markets, LLC, R. Seelaus & Co., LLC and U.S. Bancorp Investments, Inc. are acting as co-managers for this offering.

FSK intends to use the net proceeds of this offering for general corporate purposes, including potentially repaying outstanding indebtedness under credit facilities and certain notes.

This announcement does not constitute an offer to sell or a solicitation of an offer to buy any of the Notes, nor shall there be any offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

About FS KKR Capital Corp.

FSK is a leading publicly traded business development company (BDC) focused on providing customized credit solutions to private middle market U.S. companies. FSK seeks to invest primarily in the senior secured debt and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. FSK is advised by FS/KKR Advisor, LLC.

Full story available on Benzinga.com

Cohen & Steers Quality Income Realty Fund, Inc. Announces Terms of Transferable Rights Offering

PRNewswire — Mon, 08 Jun 2026 20:17:00 +0000

NEW YORK, June 8, 2026 /PRNewswire/ -- Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") announced today that its Board of Directors has approved the terms of the issuance of transferable rights ("Rights") to the holders of the Fund's common stock (par value $0.001 per share), as of the record date, June 18, 2026 (the "Record Date"). Holders of these Rights will be entitled to subscribe for additional shares of common stock (the "Offer"). The Offer to acquire additional shares of common stock will be made only by means of a prospectus supplement and accompanying prospectus, and this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any of the Fund's securities.

Cohen & Steers Capital Management, Inc. (the "Advisor") believes that incremental investments in key sectors within listed and private real estate can potentially support the distribution rate and enhance portfolio performance for all common stockholders.

Mathew Kirschner, Portfolio Manager, U.S. Real Estate at Cohen & Steers, said:
"We believe listed and private real estate are attractively valued compared with stocks and bonds, reflecting the idea that real estate has repriced and is in the early stages of a new cycle. Powerful themes—a retail renaissance, digital transformation, and aging populations—are converging with limited supply to create compelling investment opportunities across real estate. This rights offering provides investors with the potential to capitalize on these opportunities."

A portion of the proceeds from the Offer may be allocated to investments in private commercial real estate but will typically not exceed 10% of the Fund's managed assets. Additionally, the Offer provides potential to invest in new opportunities without the need to sell existing portfolio positions, which may reduce taxable events for common stockholders. It also creates potential for increased liquidity and trading volume of the Fund's shares of common stock as well as providing common stockholders an opportunity to buy new common shares below market price. Importantly, the Advisor (and not the Fund) will pay all offering expenses, including the solicitation and dealer manager fees, in support of the Offer.

Certain key terms of the Offer are as follows:

Common stockholders on the Record Date ("Record Date Stockholders") will receive one transferable Right for each share of common stock owned.
Three Rights are required to purchase one newly issued share of common stock at the Subscription Price (defined below). The Fund will not issue fractional shares, so Record Date Stockholders holding fewer than three Rights will be entitled to subscribe for one full share of common stock.
The Subscription Price will be determined by the Fund upon the expiration of the Offer, which is currently expected to be July 15, 2026, unless the Fund extends the Offer (the "Expiration Date"). The Subscription Price will be based upon a formula equal to the higher of 92.5% of the average market price on Expiration Date and the four preceding trading days on the NYSE or 90% of the average of net asset value on Expiration Date and the four preceding trading days (the "Subscription Price").
Record Date Stockholders who fully exercise all Rights initially issued to them will be permitted to subscribe ...

Full story available on Benzinga.com

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PRNewswire — Mon, 08 Jun 2026 20:01:00 +0000

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $45.0 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are acting as joint book-running managers for the offering.

The securities described above are being offered by IDEAYA pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission, or the SEC. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by request from: J.P. Morgan, by mail at J.P. Morgan ...

Full story available on Benzinga.com

Edge Copper Announces Partial Exercise of Over-Allotment Option for Public Offering and Update on Concurrent Private Placement

PRNewswire — Mon, 08 Jun 2026 14:05:00 +0000

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./

VANCOUVER, BC, June 8, 2026 /CNW/ - Edge Copper Corporation (TSXV:EDCU) ("Edge Copper" or the "Company") is pleased to announce that the underwriters of its previously announced overnight marketed offering of 30,172,414 common shares at a price of C$0.58 per common share (the "Public Offering") have exercised the over-allotment option in part to purchase an additional 2,575,000 common shares, on the same terms and conditions, on the closing date of the Public Offering, for additional proceeds to the Company of C$1,493,500, for total gross proceeds from the Public Offering of approximately C$18,993,500.

Concurrently with the closing of the Public Offering, 6,974,747 common shares of the Company will be sold in a non-brokered private placement to purchasers, including certain insiders of the Company, at a price of C$0.58 per common share, for gross proceeds of C$4,045,353 (the "Private Placement").

Aggregate gross proceeds from the Public Offering and the Private Placement are expected to be approximately C$23,038,853.

The Company proposes to use the net proceeds from the Public Offering and the Private Placement primarily to advance exploration and development of its wholly-owned Zonia Copper Project in Arizona.

Insider participation in the Private Placement is a "related party transaction" within the meaning of Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions ("MI 61-101"). Edge Copper relied on the exemption from formal valuation and minority shareholder approval requirements under section 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as the fair value of the common shares issued to insiders under the Private Placement, and the consideration paid by the insiders therefor, does not exceed 25% of Edge Copper's market capitalization. Closing of the Public Offering and the Private Placement is expected to occur on June 9, 2026, and is subject to receipt of customary regulatory approvals, including approval of the TSX Venture Exchange.

The common shares offered have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or in compliance with an applicable exemption therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these common shares in any state or jurisdiction in which such ...

Full story available on Benzinga.com

ARES CAPITAL CORPORATION ANNOUNCES INAUGURAL $1 BILLION COMMERCIAL PAPER PROGRAM

PRNewswire — Mon, 08 Jun 2026 11:30:00 +0000

NEW YORK, June 8, 2026 /PRNewswire/ -- Ares Capital Corporation ("Ares Capital" or the "Company") (NASDAQ:ARCC) announced today the establishment of its inaugural commercial paper program. The program allows the Company to issue up to a maximum aggregate amount outstanding at any time of $1 billion of short-term, unsecured commercial paper notes. The notes will be sold under customary terms in the United States commercial paper note market and will rank pari passu with the Company's other senior unsecured indebtedness. The Company expects to realize cost benefits in the commercial paper market relative to other funding sources, and it expects to use available borrowing capacity from its $5.5 billion Revolving Credit Facility as a liquidity backstop for the repayment of the notes issued under the commercial paper program. Net proceeds from the issuance of any notes pursuant to the commercial paper program are expected to be used for general corporate purposes.

Full story available on Benzinga.com

VolitionRx Announces Pricing of $4.6 Million Public Offering

PRNewswire — Sun, 07 Jun 2026 22:30:00 +0000

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants

HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. The offering included participation from both new and existing investors.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

The gross proceeds for the offering are expected to be approximately $4.6 million before deducting placement agent fees and other offering expenses and excluding the proceeds from the exercise of any warrants. The additional gross proceeds to the Company from the exercise of the warrants, if fully-exercised on a cash basis, will be approximately $2.3 million. However, no assurance can be given that any of the warrants will be exercised.

The offering is expected to close on June 9, 2026, subject to the satisfaction of customary closing conditions.

The securities in the offering are being offered by Volition pursuant to an effective shelf registration statement on Form S-3 (File No. 333-283088), initially filed with the U.S. Securities and Exchange Commission (the "SEC") on November 8, 2024, as amended, and declared effective on April 18, 2025. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying base prospectus relating to and describing the terms of the ...

Full story available on Benzinga.com